




RealRate

MEDICINAL PRODUCTS 2019

ARCA biopharma Inc.
Rank 41 of 50





RealRate

MEDICINAL PRODUCTS 2019

ARCA biopharma Inc.
Rank 41 of 50



The relative strengths and weaknesses of ARCA biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARCA biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 245% points. The greatest weakness of ARCA biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is -74%, being 68% points below the market average of -5.9%.

| Input Variable | Value in 1000 USD |
|------------------------------------|-------------------|
| Assets, Current | 6,777 |
| Assets, Non-Current | 24 |
| General and Administrative Expense | 3,879 |
| Goodwill | 0 |
| Liabilities, Current | 793 |
| Liabilities, Non-Current | 0 |
| Other Assets | 0 |
| Other Compr. Net Income | 2.0 |
| Other Expenses | -23 |
| Other Liabilities | 0 |
| Other Net Income | 0 |
| Other Revenues | 162 |
| Property, Plant and Equipment, Net | 24 |
| Research and Development | 4,239 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Liabilities | 793 |
| Assets | 6,825 |
| Expenses | 8,095 |
| Revenues | 162 |
| Stockholders Equity | 6,032 |
| Net Income | -7,933 |
| Comprehensive Net Income | -7,932 |
| Economic Capital Ratio | -74% |